hrp0094p1-3 | Adrenal A | ESPE2021

Growth-Related Characteristics of Patients <18 Years of Age with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD): Real-World Evidence from the I-CAH Registry

Farrar Mallory , He Wei , Ali Salma R , Bryce Jillian , Lawrence Neil , Baronio Federico , Claahsen-van der Grinten Hedi L. , Bonfig Walter , Krone Nils , Yonan Chuck , Ahmed S. Faisal ,

Background: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare autosomal recessive condition characterized by cortisol deficiency and elevated ACTH secretion, resulting in excess androgen production. This exposure to excess androgens contributes to advanced skeletal maturation and reduced growth in puberty. Data from the I-CAH registry were analyzed to identify growth-related characteristics of children and adolescents with...

hrp0094p2-385 | Pituitary, neuroendocrinology and puberty | ESPE2021

A Practical Method for the Evaluation of Childhood Hypophysitis: Pituitary Stalk/Basilary Artery Ratio

Torel Ergur Ayca , Şimşek Fatma , Arslan Kubra , Ali Yinanc Mehmet ,

Introduction: Childhood hypophysitis (CH) is an extremely rare entity that has difficulties in definition and displays a wide variety of symptomatology. The volume and shape of pituitary gland may increase in physiological periods such as puberty and pregnancy, it may also change in various neuroendocrine and psychiatric diseases. It is important to distinguish physiological changes observed in the pituitary, especially in puberty, from hypophysitis.F...

hrp0097p1-416 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Treatment dilemma in a prepubertal patient with ACAN mutation but without advanced bone age

Hürmüzlü Közler Selen , Gürpınar Gözde , Kilci Fatih , Koçyiğit Esra , Alanay Yasemin , Jones Jeremy , Mine Çizmecioğlu Jones Filiz

Introduction: Aggrecan is a major proteoglycan component of the articular and growth plate extracellular matrix, encoded by the ACAN gene (MIM: 155760). Although short stature and various dysmorphic findings are observed in individuals with ACAN mutations, the relationship between genotype and phenotype is not clear.Case: A 6.75-year-old pre-pubertal girl presented with disproportionate short stature. She was full term f...

hrp0097p1-541 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Prediction of Adult Height Based on Automated Bone Age Estimation in Early Puberty: A Single-Center Prospective Study

Huseyin Yigit Murat , Yesiltepe Mutlu Gul , Eviz Elif , Hatun Sukru

Introduction: In cases of precocious puberty, an important factor in making treatment decisions is when adult height estimates based on bone age (BA) determination are behind midparental height. In Turkey, clinicians often use the Greulich Pyle (GP) atlas to determine BA, which can lead to significant differences between assessors. The aim of this study was to compare estimated adult height (EAH) calculations based on BA determined by the automated BoneXpert m...

hrp0097p1-296 | GH and IGFs | ESPE2023

The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys

Zhang Ying , Chen Ruimin

Objective: In boys during puberty who were undergoing recombinant human growth hormone (rhGH) treatment, we compared the therapeutic efficacy and any adverse reactions, of co-therapy with letrozole/gonadotropin releasing hormone analog (GnRHa).Methods: Fifty-six pubertal growth hormone deficiency (GHD) boys were studied, they were treated with the combination of letrozole and rhGH (letrozole group) or GnRHa and rhGH (GnR...

hrp0097p2-301 | Late Breaking | ESPE2023

Progression in height and bone age during the first year of long-term growth hormone therapy in pre adolescent GHD children

Li Yan , Xinran Chen , Chunzhu Gong

Key words: growth hormone defificiency,growth hormone, height,bone ageObjective: To evaluate the height and bone age (BA) of prepubertal growth hormone deficiency (GHD) children in the first year after long-term growth hormone treatment.Methods: According to the degree of bone age lag before treatment,36 prepubertal GHD children were divided into two groups&#xF...

hrp0095p1-23 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Comparison of adult height prediction models against the average height of the Mexican population.

Gabriela Chávez-Vázquez Ana , Klünder-Klünder Miguel , Guadalupe Garibay-Nieto Nayely , López-González Desirée , Liliana Miranda-Lora América

Background: Adult height prediction models (AHP) were designed several decades ago based on the Caucasian population, hence they are not adapted to our population’s characteristics and secular changes. Technological advances have improved the accuracy of bone age (BA) reading through automated analysis, which has been incorporated into new AHP models, but have not been evaluated in the Mexican population.Objective:...

hrp0092p2-192 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Shox-Haploinsufficiency Intra-Familial Phenotipic Variability and the Impact on Final Height: Report of a Pedigree

Maggio Maria Cristina , Mulè Flavia , Cardella Francesca , Corsello Giovanni

SHOX haploinsufficiency (SHOX-D) is a genetic cause of disharmonic short stature. However, the different impact on phenotype can show differences between patients with the same genotype.GH ameliorates final height, with significant differences between patients for the putative role of environmental factors who can influence growth.We describe the case of two sisters with SHOX-D (target height: 146.8 cm (-2.6SDS); mother: 146.5 cm; ...

hrp0082p2-d3-316 | Bone (2) | ESPE2014

Bone Size and Bone Mineral Content in Adolescents and Young Adults with Eating Disorders

Mason Avril , Shepherd Sheila , Oakley Charlotte , Thrower Michelle , Kyriakou Andreas , Shaikh Guftar , Ahmed Syed Faisal

Background: There is growing concern about the impact of eating disorders on the bone heath during adolescence where peak bone mass acquisition is of paramount importance.Method: A total of 85 patients (77F/8M, 75% anorexia nervosa(AN) and 25% atypical eating disorder), median age 15.2 years (range, 10.9–19.8) and median BMI SDS −1.3 (−4.7 to 0.8) attended the bone densitometry service between Jan 2009 and Dec 2013 for total body (TB) an...

hrp0097p1-425 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Recombinant human growth hormone treatment for osteogenesis imperfecta: report of two cases

Eduardo Cruvinel Pinto Luís , Scheidemantel Aline , Junqueira Soares Gabriel , Ângela Ramires de Carvalho Julienne

Background: Osteogenesis imperfecta (OI) is a genetic connective tissue disorder with variable phenotype, mainly characterized by bone fragility, short stature and non-skeleton findings. Since growth failure is a predominant feature of OI, recombinant human growth hormone (rhGH) has been suggested as a potential intervention. We describe two boys with OI type I treated with rhGH.Case Reports: Patient 1 had the first frac...